A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.

Gang AnDaobin ZhouShu ChengKeshu ZhouJianyong LiJian-Feng ZhouLiping XieJie JinLiye ZhongLingzhi YanHaiyi GuoChenmu DuJinhua ZhongYiling YuBinghao WuLugui Qiu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Zanubrutinib achieved a high rate of response that was durable and deep in patients with R/R WM across all subgroups, and potentially confers a positive benefit-risk profile for WM.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
hodgkin lymphoma
open label
double blind